See more : Mahindra & Mahindra Limited (MHID.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Intec Pharma Ltd (NTEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intec Pharma Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Melar Acquisition Corp. I (MACI) Income Statement Analysis – Financial Results
- Grown Rogue International Inc. (GRUSF) Income Statement Analysis – Financial Results
- Atlas Corp. (ATCO-PD) Income Statement Analysis – Financial Results
- Renewable Japan Co., Ltd. (9522.T) Income Statement Analysis – Financial Results
- Delivra Health Brands Inc. (DHBUF) Income Statement Analysis – Financial Results
Intec Pharma Ltd (NTEC)
About Intec Pharma Ltd
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.74M | 26.66M | 35.40M | 24.30M | 10.75M | 4.79M | 3.41M | 2.59M |
| General & Administrative | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Other Expenses | 0.00 | -1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.83M | 33.45M | 43.33M | 29.41M | 13.82M | 7.54M | 6.00M | 5.33M |
| Cost & Expenses | 13.83M | 33.45M | 43.33M | 29.44M | 13.85M | 7.56M | 6.02M | 5.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 15.00K | 23.00K | 17.00K | 16.00K | 15.37K | 23.00K | 24.41K |
| Depreciation & Amortization | 1.20M | 854.00K | 859.00K | 829.00K | 701.00K | 742.38K | 585.00K | 624.84K |
| EBITDA | -12.80M | -46.09M | -42.56M | -28.22M | -12.65M | -6.39M | -5.09M | -4.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.83M | -33.45M | -43.33M | -29.44M | -13.85M | -7.56M | -6.02M | -5.36M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -175.00K | -13.52M | -112.00K | 375.00K | 484.00K | 421.40K | 325.00K | 74.66K |
| Income Before Tax | -14.00M | -46.96M | -43.44M | -29.06M | -13.36M | -7.14M | -5.69M | -5.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 124.00K | 638.00K | 103.00K | 29.00K | 500.00K | 436.77K | 348.00K | 99.07K |
| Net Income | -14.13M | -47.60M | -43.54M | -29.09M | -13.36M | -7.14M | -5.69M | -5.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| EPS Diluted | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| Weighted Avg Shares Out | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
| Weighted Avg Shares Out (Dil) | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
Intec Pharma Reports First Half 2016 Financial Results
Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies
Source: https://incomestatements.info
Category: Stock Reports